Dimitar B Nikilov

Title: **Dimitar B. Nikilov: Innovator in Nucleotidylyltransferase Engineering**

Introduction

Dimitar B. Nikilov, based in New York, NY, is a distinguished inventor recognized for his innovative contributions to enzymatic methods and nucleotide sugar synthesis. With a total of two patents to his name, his work has the potential to impact various areas within biochemistry and biotechnology.

Latest Patents

Nikilov's most recent patents focus on active-site engineering of nucleotidylyltransferases and methods for synthesizing both natural and 'unnatural' UDP- and TDP-nucleotide sugars. These inventions introduce mutant nucleotidylyl-transferases that exhibit altered substrate specificity, along with methods for producing these enzymes. The patents also encompass techniques for synthesizing desired nucleotide sugars utilizing natural and/or modified nucleotidyltransferases. Additionally, the patents present new glycosyl phosphates and methods for their production, showcasing advancements in biochemical synthesis.

Career Highlights

Nikilov has made significant strides in his career while working at renowned institutions such as the Sloan-Kettering Institute for Cancer Research. His role at this prestigious organization underlines his dedication to advancing cancer research through biochemical innovations. His pioneering work in enzymatic methods positions him as a key figure in the field.

Collaborations

One of his notable collaborations includes working alongside Jon S. Thorson, a fellow researcher whose expertise complements Nikilov's innovative endeavors. Their partnership highlights the importance of collaboration in driving scientific advancements.

Conclusion

Dimitar B. Nikilov's contributions to the field of nucleotidylyltransferases and enzymatic synthesis represent significant innovations that have the potential to transform biochemistry. His ongoing research and patent developments signify a promising future, both for his career and the scientific community at large. Through his work, he continues to illuminate the path for future innovations in biotechnology.